Literature DB >> 23138650

Presenilin-1 adopts pathogenic conformation in normal aging and in sporadic Alzheimer's disease.

Lara Wahlster1, Muriel Arimon, Navine Nasser-Ghodsi, Kathryn Leigh Post, Alberto Serrano-Pozo, Kengo Uemura, Oksana Berezovska.   

Abstract

Accumulation of amyloid-β (Aβ) and neurofibrillary tangles in the brain, inflammation and synaptic and neuronal loss are some of the major neuropathological hallmarks of Alzheimer's disease (AD). While genetic mutations in amyloid precursor protein and presenilin-1 and -2 (PS1 and PS2) genes cause early-onset familial AD, the etiology of sporadic AD is not fully understood. Our current study shows that changes in conformation of endogenous wild-type PS1, similar to those found with mutant PS1, occur in sporadic AD brain and during normal aging. Using a mouse model of Alzheimer's disease (Tg2576) that overexpresses the Swedish mutation of amyloid precursor protein but has normal levels of endogenous wild-type presenilin, we report that the percentage of PS1 in a pathogenic conformation increases with age. Importantly, we found that this PS1 conformational shift is associated with amyloid pathology and precedes amyloid-β deposition in the brain. Furthermore, we found that oxidative stress, a common stress characteristic of aging and AD, causes pathogenic PS1 conformational change in neurons in vitro, which is accompanied by increased Aβ42/40 ratio. The results of this study provide important information about the timeline of pathogenic changes in PS1 conformation during aging and suggest that structural changes in PS1/γ-secretase may represent a molecular mechanism by which oxidative stress triggers amyloid-β accumulation in aging and in sporadic AD brain.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23138650      PMCID: PMC3552123          DOI: 10.1007/s00401-012-1065-6

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  72 in total

1.  Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment.

Authors:  R D Terry; E Masliah; D P Salmon; N Butters; R DeTeresa; R Hill; L A Hansen; R Katzman
Journal:  Ann Neurol       Date:  1991-10       Impact factor: 10.422

2.  Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques.

Authors:  Robert M Koffie; Melanie Meyer-Luehmann; Tadafumi Hashimoto; Kenneth W Adams; Matthew L Mielke; Monica Garcia-Alloza; Kristina D Micheva; Stephen J Smith; M Leo Kim; Virginia M Lee; Bradley T Hyman; Tara L Spires-Jones
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-19       Impact factor: 11.205

3.  4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease.

Authors:  L M Sayre; D A Zelasko; P L Harris; G Perry; R G Salomon; M A Smith
Journal:  J Neurochem       Date:  1997-05       Impact factor: 5.372

4.  Familial Alzheimer's disease presenilin 1 mutations cause alterations in the conformation of presenilin and interactions with amyloid precursor protein.

Authors:  Oksana Berezovska; Alberto Lleo; Lauren D Herl; Matthew P Frosch; Edward A Stern; Brian J Bacskai; Bradley T Hyman
Journal:  J Neurosci       Date:  2005-03-16       Impact factor: 6.167

5.  Quantitative synaptic alterations in the human neocortex during normal aging.

Authors:  E Masliah; M Mallory; L Hansen; R DeTeresa; R D Terry
Journal:  Neurology       Date:  1993-01       Impact factor: 9.910

6.  An over-oxidized form of superoxide dismutase found in sporadic amyotrophic lateral sclerosis with bulbar onset shares a toxic mechanism with mutant SOD1.

Authors:  Stefania Guareschi; Emanuela Cova; Cristina Cereda; Mauro Ceroni; Elena Donetti; Daryl A Bosco; Davide Trotti; Piera Pasinelli
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-13       Impact factor: 11.205

Review 7.  Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease.

Authors: 
Journal:  Neurobiol Aging       Date:  1997 Jul-Aug       Impact factor: 4.673

Review 8.  L-deprenyl in the treatment of mild dementia of the Alzheimer type: results of a 15-month trial.

Authors:  W J Burke; W H Roccaforte; S P Wengel; B L Bayer; A E Ranno; N K Willcockson
Journal:  J Am Geriatr Soc       Date:  1993-11       Impact factor: 5.562

9.  Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease.

Authors:  T Kawarabayashi; L H Younkin; T C Saido; M Shoji; K H Ashe; S G Younkin
Journal:  J Neurosci       Date:  2001-01-15       Impact factor: 6.167

10.  Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease.

Authors:  P V Arriagada; K Marzloff; B T Hyman
Journal:  Neurology       Date:  1992-09       Impact factor: 9.910

View more
  29 in total

1.  Interrelationship between Changes in the Amyloid β 42/40 Ratio and Presenilin 1 Conformation.

Authors:  Katarzyna Marta Zoltowska; Masato Maesako; Oksana Berezovska
Journal:  Mol Med       Date:  2016-07-05       Impact factor: 6.354

2.  The presenilin loop region is essential for glycogen synthase kinase 3 β (GSK3β) mediated functions on motor proteins during axonal transport.

Authors:  Rupkatha Banerjee; Zoe Rudloff; Crystal Naylor; Michael C Yu; Shermali Gunawardena
Journal:  Hum Mol Genet       Date:  2018-09-01       Impact factor: 6.150

Review 3.  Three dimensions of the amyloid hypothesis: time, space and 'wingmen'.

Authors:  Erik S Musiek; David M Holtzman
Journal:  Nat Neurosci       Date:  2015-06       Impact factor: 24.884

Review 4.  Dynamic Nature of presenilin1/γ-Secretase: Implication for Alzheimer's Disease Pathogenesis.

Authors:  Katarzyna Marta Zoltowska; Oksana Berezovska
Journal:  Mol Neurobiol       Date:  2017-03-22       Impact factor: 5.590

Review 5.  Neuronal Ryanodine Receptors in Development and Aging.

Authors:  Nawaf Abu-Omar; Jogita Das; Vivian Szeto; Zhong-Ping Feng
Journal:  Mol Neurobiol       Date:  2017-01-19       Impact factor: 5.590

6.  Convergence of pathology in dementia with Lewy bodies and Alzheimer's disease: a role for the novel interaction of alpha-synuclein and presenilin 1 in disease.

Authors:  Ashley R Winslow; Simon Moussaud; Liya Zhu; Kathryn L Post; Katherine L Post; Dennis W Dickson; Oksana Berezovska; Pamela J McLean
Journal:  Brain       Date:  2014-05-24       Impact factor: 13.501

7.  Oxidative stress and lipid peroxidation are upstream of amyloid pathology.

Authors:  Muriel Arimon; Shuko Takeda; Kathryn L Post; Sarah Svirsky; Bradley T Hyman; Oksana Berezovska
Journal:  Neurobiol Dis       Date:  2015-06-21       Impact factor: 5.996

Review 8.  Mechanisms of action of amyloid-beta and its precursor protein in neuronal cell death.

Authors:  Yong Qi Leong; Khuen Yen Ng; Soi Moi Chye; Anna Pick Kiong Ling; Rhun Yian Koh
Journal:  Metab Brain Dis       Date:  2019-12-06       Impact factor: 3.584

Review 9.  Protective Effects of Polysaccharides in Neurodegenerative Diseases.

Authors:  Yinying Wang; Rongsha Chen; Zhongshan Yang; Qian Wen; Xia Cao; Ninghui Zhao; Jinyuan Yan
Journal:  Front Aging Neurosci       Date:  2022-07-04       Impact factor: 5.702

Review 10.  Deconstructing mitochondrial dysfunction in Alzheimer disease.

Authors:  Vega García-Escudero; Patricia Martín-Maestro; George Perry; Jesús Avila
Journal:  Oxid Med Cell Longev       Date:  2013-06-11       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.